title: Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability.
abstract: The Parallel Artificial Membrane Permeability Assay (PAMPA) has been successfully introduced into the pharmaceutical industry to allow useful predictions of passive oral absorption. Over the last 5 years, researchers have modified the PAMPA such that it can also evaluate passive blood-brain barrier (BBB) permeability. This paper compares the permeability of 19 structurally diverse, commercially available drugs assessed in four different PAMPA models: (1) a PAMPA-BLM (black lipid membrane) model, (2) a PAMPA-DS (Double Sink) model, (3) a PAMPA-BBB model and (4) a PAMPA-BBB-UWL (unstirred water layer) model in order to find the most discriminating method for the prediction of BBB permeability. Both the PAMPA-BBB model and the PAMPA-BLM model accurately identified compounds which pass the BBB (BBB+) and those which poorly penetrate the BBB (BBB-). For these models, BBB+ and BBB- classification ranges, in terms of permeability values, could be defined, offering the opportunity to validate the paradigm with in vivo data. The PAMPA models were subsequently applied to a set of 14 structurally diverse internal J&J candidates with known log (brain/blood concentration) (LogBB) values. Based on these LogBB values, BBB classifications were established (BBB+: LogBB0 >or=; BBB-: LogBB<0). PAMPA-BLM resulted in three false positive identifications, while PAMPA-BBB misclassified only one compound. Additionally, a Caco-2 assay was performed to determine the efflux ratio of all compounds in the test set. The false positive that occurred in both models was shown to be related to an increased efflux ratio. Both the PAMPA-BLM and the PAMPA-BBB models can be used to predict BBB permeability of compounds in combination with an assay that provides p-gp efflux data, such as the Caco-2 assay.
authors.affiliation: Chempharm Development, Johnson & Johnson Pharmaceutical Research & Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium. jmensch@its.jnj.com
authors.forename: Jurgen
authors.initials: J
authors.lastname: Mensch
authors.forename: Anouche
authors.initials: A
authors.lastname: Melis
authors.forename: Claire
authors.initials: C
authors.lastname: Mackie
authors.forename: Geert
authors.initials: G
authors.lastname: Verreck
authors.forename: Marcus E
authors.initials: ME
authors.lastname: Brewster
authors.forename: Patrick
authors.initials: P
authors.lastname: Augustijns
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D018938:Caco-2 Cells; D002463:Cell Membrane Permeability; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008297:Male; D008567:Membranes, Artificial; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D011237:Predictive Value of Tests; D051381:Rats; D012995:Solubility; D013329:Structure-Activity Relationship; D013552:Swine; D013816:Thermodynamics
chemical_list: D008055:Lipids; D008567:Membranes, Artificial; D004364:Pharmaceutical Preparations